Risk! Evidence! Guidelines! Fine tuning type 2 diabetes management in adults
Early adoption in primary care of cardiorenal metabolic medicines in adult type 2 diabetes
(Episode 3)
What’s in it for me?
We value your feedback and would appreciate your help in shaping future podcasts. After listening, click here to complete the evaluation form.
Please download your CPD accreditation certificate by clicking here and record your learning reflections to support your annual professional revalidation.
GP and Director. Croydon GP Collaborative, Croydon and the James O'Riordan Medical Centre, Sutton
Lead Clinical Pharmacist, Haringey GP Federation, London
This CPD-accredited podcast will cover the following topics:
- The significance of SGLT2 inhibitors in managing cardio-renal-metabolic conditions and their role in the Type 2 Diabetes Guidelines
- The role of primary care in implementing SGLT2i therapies and the importance of starting these treatments early across the continuum of patient care
- Top tips and effective strategies to overcome common barriers to the low uptake of SGLT2i in clinical practice, despite national and international guidelines recommending early initiation of these therapies
- The significance of working within a multidisciplinary team and the necessity of involving team members in the prescribing of SGLT2i therapy
For full prescribing and safety information in relation to individual SGLT2 inhibitors, please refer to relevant summary of product characteristics as SGLT2 inhibitor indications vary.
Abbreviations used in this podcast:
ARRS, Additional Roles Reimbursement Scheme; CKD, chronic kidney disease; DPP-4, dipeptidyl peptidase-4; HbA1c, glycated haemoglobin; HCP, healthcare professional; MDT, multidisciplinary team; NICE, National Institute for Health and Care Excellence; PA, personal assistant; SGLT2, sodium-glucose cotransporter-2; SPC, Summary of Products Characteristics
Podcasts 1 and 2 of this series will cover the following topics:
- The evolution in the evidence that currently guides the management of adults living with type 2 diabetes
- The relevance of using QRISK tools in primary care to calculate and predict cardiovascular risk early in Type 2 Diabetes Progression
- The importance of moving away from glucocentric approach to Type 2 Diabetes management thinking beyond reductions: The role of the UK Prospective Diabetes Study(UKPDS). The significance of the EMPA-REG OUTCOME trial in holistic management of Type 2 Diabetes
How has the management of adult type 2 diabetes changed in recent decades?
Speaker: Professor Mike Cummings
What tools are available to assess cardiovascular risk in adult type 2 diabetes?
Speaker: Professor Ahmet Fuat
PC-GB-111731 | July 2025
The content on this website is in relation to adult patients.
Empagliflozin is not recommended in severe hepatic impairment, breastfeeding, Type 1 diabetes and is contraindicated in patients with hypersensitivity to the active ingredient or any of its excipients. Empagliflozin should be avoided in pregnancy.
Please consult the SmPC for full details regarding adverse events, monitoring requirements and interactions prior to prescribing JARDIANCE®.
- JARDIANCE® (empagliflozin) UK Summary of Product Characteristics (SmPC). Available at:
http://www.medicines.org.uk/emc/medicine/28973.
JARDIANCE® is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- as monotherapy when metformin is considered inappropriate due to intolerance
- in addition to other medicinal products for the treatment of diabetes1
JARDIANCE® is indicated in adults for the treatment of chronic kidney disease.1
JARDIANCE® is indicated in adults for the treatment of symptomatic chronic heart failure.1
PC-GB-109995 V4 | October 2025